RZLT (Rezolute Inc) Earnings per share for the last four quarters

Rezolute Corp (RZLT) - corporate logo

Rezolute, Inc. relies on contract manufacturing and outsourced clinical trial management for global scaling. The company is implementing ESG standards by optimizing laboratory energy consumption and adhering to bioethics. The narrow niche of rare endocrine pathologies creates binary risks. The relative change in EPS YoY (ttm) demonstrates profit dynamics, where the indicator stands at 19.50, helping to assess the asset's fundamental momentum.

RZLT rezolutebio.com Net earnings per share (EPS TTM) (02/11/2024 - 11/16/2026)

RZLT (Rezolute, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:RZLT (Rezolute Inc)
Core merchandise of Rezolute Bio

The success of Rezolute, Inc. (RZLT) correlates directly with the outcomes of clinical trials for molecules targeting hyperinsulinism, making the control of R&D expenditures a critical factor for sustainability. By analyzing the annual EPS growth rate over the last 12 months, investors assess the trend of net income per share to determine the business's ability to generate real income and withstand inflationary pressure amid tight monetary policy.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS